Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Family with sequence similarity 13 member A (FAM13A) is a cytoplasmic and nuclear protein characterized by an N-terminal Rho GTPase-activating protein (RhoGAP) domain and C-terminal coiled-coil domains. It regulates RhoA GTPase activity and modulates actin cytoskeleton dynamics, contributing to processes such as cilia movement, cellular remodeling, and epithelial-mesenchymal transition. FAM13A also influences Wnt/β-catenin signaling by recruiting and modulating components of the β-catenin destruction complex. Genome-wide association studies have linked genetic variants in FAM13A to reduced lung function and higher risk for chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, asthma, and lung cancer. It also acts as a modifier gene in cystic fibrosis and has been implicated in insulin sensitivity and adipose tissue biology. FAM13A is regulated through Akt- and PP2A-mediated phosphorylation, which controls its nuclear-cytoplasmic distribution. There are currently no drugs that directly target FAM13A, and no direct safety issues are known for its modulation.
Not applicable; no drugs directly target FAM13A as of the current literature
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Family with sequence similarity 13 member A (FAM13A).